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Abstract Doxycycline has been demonstrated to reduced
left ventricular (LV) remodeling, but its effect in patients
with ST-elevation myocardial infarction (STEMI) and a
baseline occluded [thrombolysis in myocardial infarction
(TIMI) flow grade B1] infarct-related artery (IRA) is
unknown. According to the baseline TIMI flow grade, 110
patients with a first STEMI were divided into 2 groups.
Group 1: 77 patients with TIMI flow B1 (40 patients treated
with doxycycline and 37 with standard therapy, respec-
tively), and a Group 2: 33 patients with TIMI flow 2–3 (15
patients treated with doxycycline and 18 with standard
therapy, respectively). The two randomized groups were
well matched in baseline characteristics. A 2D-Echo was
performed at baseline and at 6 months, together with a
coronary angiography, for the remodeling and IRA patency
assessment, respectively. The LV end-diastolic volume
index (LVEDVi) decreased in Group 2 [-3 mL/m2 (IQR:
-12 to 4 mL/m2)], and increased in Group 1 [6 mL/m2
(IQR: -2 to 14 mL/m2)], (p = 0.001). In Group 2,
LVEDVi reduction was similar regardless of drug therapy,
while in Group 1 the LVEDVi was smaller in patients
treated with doxycycline as compared to control [3 mL/m2
(IQR: -3 to 8 mL/m2) vs. 10 mL/m2 (IQR: 1–27 mL/m2),
p = 0.006]. A similar pattern was observed also for LV
end-systolic volume and ejection fraction. In STEMI
patients at higher risk, as those with a baseline TIMI flow
grade B1, doxycycline reduces LV remodeling.
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In recent years, large interest has been focused on the
open [thrombolysis in myocardial infarction (TIMI) flow
2–3] infarct-related artery (IRA) of patients with acute
ST-elevation myocardial infarction (STEMI) before
primary percutaneous coronary intervention (PCI),
which may imply shorter ischemia time, a smaller
infarct size [1–3], and better left ventricular (LV)
function [1, 3, 4], and patient outcome [5, 6]. Con-
versely, an occluded IRA (TIMI flow grade B1) before
primary PCI, which is observed in almost 2/3 of patients
with STEMI [2], is associated with increased LV
remodeling despite an optimal epicardial mechanical
recanalization (post-PCI TIMI flow grade 3) [4]. This
ominous relationship between low baseline TIMI flow
grade and LV remodeling has been attributed to differ-
ent factors [7–9] including a greater ischemia/reperfu-
sion injury [10].
In patients with STEMI and LV dysfunction success-
fully treated with primary PCI, we recently demonstrated
that a timely short-term therapy with doxycycline, the most
potent metalloproteinases (MMPs) inhibitor of the tetra-
cycline class of antibiotics, reduced both 6-month LV
remodeling and infarct size [11]. Several pleiotropic
properties of doxycycline related mainly to its ability to act
as metalloproteinases (MMPs) inhibitor can explain these
beneficial effects [12].
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On the base of the recently performed TIPTOP (early
short-term doxycycline therapy in patients with acute
myocardial infarction and left ventricular dysfunction to
prevent the ominous progression to adverse remodeling)
randomized trial [11], we therefore set out to analyze the
relationship between pre-PCI IRA TIMI flow and the
6-month LV remodeling in relation to doxycycline therapy.
Methods
Study design, patients and procedures
The TIPTOP trial has been already descripted in detail
[11]. In brief, TIPTOP trial is a prospective, phase-2, sin-
gle-center, randomized, open-label controlled trial in which
110 patients older than 18 years with acute STEMI and LV
ejection fraction (LVEF) \40 % were randomly assigned
in a 1:1 ratio to receive doxycycline or standard care. All
patients were treated with primary PCI, including stenting
of the IRA, and received medical therapy for STEMI and
LV dysfunction in accordance with standard and recom-
mended practice. Doxycycline (Bassado; Pfizer Italia s.r.l.)
was administered at 100 mg oral dose immediately after
primary PCI and then every 12 h for 7 days. The antimi-
crobial dose we used ensures plasma levels of doxycycline
similar to those obtained with higher doses used in the
experimental model where the doxycycline has been
proved effective in inhibiting MMPs [13], and preventing
abdominal aortic aneurysm [13] and post-infarction LV
remodeling [14, 15]. The R ST-segment elevation imme-
diately before primary PCI was considered as a surrogate
of the area of myocardium at risk [16]. The pre-defined
primary endpoint of the TIPTOP Trial was the percent
change from baseline to 6 months in echocardiographic LV
end-diastolic volume index (LVEDVi).
For the present study, pre- and post-primary PCI angio-
graphic flow grade was re-analyzed by two experts (AM and
GP) who were not associated with the original trial, and who
were unaware of the treatment group assignments and
clinical outcomes. Blood flow in the IRA was graded
according to the TIMI classification [17]. Collateral circu-
lation was quantified according to Rentrop et al. [18]. Left
ventricular remodeling was defined as the change from
baseline to 6 months (D) in echocardiographic LVEDVi.
Statistical analysis
Discrete data were summarized as frequencies, whereas
continuous data were summarized as mean ± SD or
median and interquartile range (IQR) when appropriate.
The x2 test or Fisher’s exact test was used for comparison
of categorical variables, and the unpaired and paired
2-tailed Student t test or Mann–Whitney–Wilcoxon rank-
sum test was used to detect differences among continuous
variables. Non-parametric tests were used for analyzing the
non-normally distributed (Shapiro–Wilk test) baseline
LVEDVi and LVESVi, D LVEDVi and LVESVi, R ST-
segment elevation, troponin I peak, creatine kinase-MB
peak and pro brain natriuretic peptide (pro-BNP) peak. To
examine the unique contribution of doxycycline on LV
remodeling, a hierarchical multiple regression analysis was
performed, after logarithmic or square root transforming
for the non-normally distributed variables. The choice of
variables to be included in the multivariate model was
based on a conceptual framework describing the hierar-
chical relationships between the major determinants that
could explain the LV remodeling. The single variables that
could explain LV remodeling were entered in two steps. In
step 1, D LVEDVi was the dependent variable while age,
diabetes, hypertension, R ST-segment elevation pre-PCI
and post-PCI (as a measure of the area at risk and myo-
cardial reperfusion effectiveness, respectively), troponin I
peak or CK-MB peak (as a measure of the infarct size), and
pro-BNP peak (as a measure of LV wall stress) were the
independent variables. In step 2, ACE inhibitors/ARBs,
and beta adrenergic blockers, which represent the corner-
stone of anti-remodeling therapy for acute STEMI patients,
were entered into the step 2 equation. Finally, doxycycline
was entered into the step 3 equation. All tests were two
sided, and a p value \0.05 was considered statistically
significant. Analyses were performed with SPSS software,
version 19 (IBM Corp, Somers, NY).
Results
Baseline characteristics
Patients were divided into two groups depending on the
baseline IRA TIMI flow grade: group 1, with TIMI flow
grade B1 (77 patients), and group 2 with TIMI flow grade
2–3 (33 patients). Baseline characteristics of the patients
are shown in Table 1. A TIMI flow B1 was associated with
younger age and lower prevalence of diabetes and hyper-
tension. Reduced pre-procedural TIMI flow grade was also
associated with a larger myocardial area at risk, as indi-
rectly showed by pre-PCI R ST-segment elevation.
Of the 77 patients with baseline TIMI flow grade B1, 40
patients [52 %] received doxycycline therapy (in addition
to standard therapy), and 37 patients (48 %) received
standard therapy, respectively. Among 33 patients with
baseline TIMI flow grade 2–3, 15 patients (45 %) received
doxycycline therapy (in addition to standard therapy) and
18 patients (55 %) received standard therapy, respectively.
The baseline characteristics according to the TIMI flow and
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doxycycline therapy are shown in Table 2. No significant
difference was observed in relation to the study drug,
regardless of the baseline TIMI flow grade.
Clinical findings
Overall, 6-month mortality was 4.6 % (5 of 110 patients): 4
patients (5 %) with baseline TIMI flow grade B1 [one in the
doxycycline group (2 %), and three in the control group
(8 %), respectively] died of acute heart failure during the first
month after index myocardial infarction; one patient (3 %)
with baseline TIMI flow grade 2–3 in the control group died
of ischemic stroke 5 months after MI. One patient with
baseline TIMI flow grade B1 in the control group had a non-
fatal recurrent MI, and this patient was excluded from
6-month evaluation. Ten patients with baseline TIMI flow
grade B1 (13 %), three in the doxycycline group (7 %) and
seven in the control group (19 %), and one patient with
baseline TIMI flow grade 2–3 (3 %) randomized to doxy-
cycline group had a worsening NYHA class III–IV and/or
Table 1 Baseline and
procedural characteristics
according to the baseline TIMI
flow
Continuous data are presented
as mean ± SD or as median
[interquartile range] when
appropriate
ACE denotes angiotensin-
converting enzyme, ARB
angiotensin II receptor blocker,
IRA infarct-related artery, LAD
left anterior descending artery,
LVEF left ventricular ejection
fraction, LVEDVi left
ventricular end-diastolic volume
index, LVESVi left ventricular
end-systolic volume index, PCI
primary percutaneous coronary
intervention, TIMI thrombolysis
in myocardial infarction, TnI
troponin I, CK-MB creatine
kinase-MB, BNP brain
natriuretic peptide, R STe sum
of ST-elevation
Variables Group 1 (TIMI flow B1)
(n = 77)
Group 2 (TIMI flow 2–3)
(n = 33)
p value
Age (years) 69 ± 12 71 ± 10 0.29
Male sex (%) 71 64 0.42
Hypertension (%) 39 61 0.04
Diabetes (%) 9 39 0.001
Dyslipidemia (%) 23 24 0.92
Smoke (%) 39 36 0.80
Ischemia time (min) 272 ± 205 280 ± 220 0.86
Heart rate (beats/min) 77 ± 14 83 ± 16 0.05
Systolic blood pressure (mmHg) 129 ± 28 130 ± 29 0.87
Killip class 1.5 ± 0.7 1.4 ± 0.8 0.71
Anterior location (%) 91 97 0.27
R STe pre-PCI (mm) 15.0 [11.3–23.8] 9.2 [5.6–15.4] 0.001
R STe post-PCI (mm) 5.3 [3.1–10.4] 3.9 [1.9–4.8] 0.10
LVEDVi (mL/m2) 45 [39–54] 48 [39–62] 0.11
LVESVi (mL/m2) 28 [23–34] 32 [24–42] 0.12
LVEF (%) 37 ± 7 36 ± 7 0.63
LAD (%) 90 91 0.84
Multivessel disease (%) 48 51 0.34
Collateral grade Rentrop1 (%) 1.3 3 0.53
Number of treated lesions
(mean)
1.5 ± 0.7 1.3 ± 0.5 0.73
Procedural success (%) 100 100 1.00
Stenting of IRA (%) 100 100 1.00
Multiple stenting (%) 31 42 0.40
Abciximab use (%) 94 94 0.93
Total length of stenting (mm) 22 ± 11 25 ± 9 0.21
IRA TIMI flow grade 3 after
PCI (%)
100 100 1.00
Symptom onset to balloon time
(min)
241 ± 203 246 ± 223 0.91
Procedural time (min) 32 ± 18 34 ± 16 0.49
TnI peak (ng/ml) 248 [119–416] 84 [39–221] 0.001
CK-MB (IU/L) 316 [206–450] 141 [76–241] 0.001
Pro-BNP Peak (pg/mL) 3,111 [1,896–6,544] 4,795 [2,439–9,451] 0.18
Aspirin (%) 96 100 0.61
Thienopyridine (%) 100 100 1.00
Statin (%) 100 100 1.00
Beta adrenergic blocker (%) 84 88 0.76
ACE inhibitor/ARB (%) 77 90 0.14
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hospital readmission for congestive heart failure. Overall,
the rate of composite of death, myocardial infarction and
congestive heart failure was 19 % within the group with
baseline TIMI flow grade B1 (30 % in the control group and
10 % in the doxycycline group, respectively; p = 0.04), and
9 % within the group with baseline TIMI flow grade 2–3
(11 % in the control group and 7 % in the doxycycline group,
respectively; p = 1.0). Out of the 104 survived patients, 66
Table 2 Baseline and procedural characteristics according to the baseline TIMI flow and doxycycline therapy
Group 1 (TIMI flow B1) (n = 77) p Group 2 (TIMI flow 2–3) (n = 33) p
Doxycycline
(n = 40)
Control (n = 37) Doxycycline
(n = 15)
Control (n = 18)
Age (years) 68 ± 12 70 ± 12 0.43 73 ± 8 69 ± 12 0.26
Male sex (%) 75 67 0.47 67 61 0.71
Hypertension (%) 42 35 0.51 60 61 0.95
Diabetes (%) 7 11 0.61 33 44 0.51
Dyslipidemia (%) 30 16 0.15 27 22 0.77
Smoke (%) 37 40 0.78 40 33 0.69
Ischemia time (min) 275 ± 192 269 ± 221 0.90 267 ± 139 291 ± 274 0.76
Heart rate (beats/min) 74 ± 13 80 ± 15 0.56 84 ± 18 83 ± 15 0.82
Systolic blood pressure (mmHg) 129 ± 30 128 ± 26 0.85 133 ± 32 127 ± 27 0.58
Killip Class 1.4 ± 0.7 1.5 ± 0.7 0.69 1.3 ± 0.6 1.5 ± 0.9 0.30
Anterior location (%) 95 86 0.19 100 94 0.35
R STe pre-PCI (mm) 17 [10–25] 14 [12–23] 0.90 9.2 [6–15] 6 [5–15] 0.24
R STe post (mm) 6 [3–11] 5 [3–9] 0.72 3.9 [2–5] 4 [2–5] 0.37
LVEDVi (mL/m2) 45 [39–54] 45 [39–53] 0.68 48 [39–62] 56 [38–65] 0.44
LVESVi (mL/m2) 28 [24–34] 28 [23–35] 0.75 32 [24–42] 34 [24–45] 0.41
LVEF (%) 37 ± 7 36 ± 7 0.49 36 ± 7 35 ± 8 0.27
LAD (%) 92 86 0.39 93 89 0.66
Multivessel disease (%) 30 32 0.96 47 55 0.48
Collateral grade Rentrop 1 (%) 2.5 0 0.33 0 5.9 0.35
Number of treated lesions (mean) 1.2 ± 0.5 1.3 ± 0.6 0.30 1.6 ± 0.9 1.4 ± 0.6 0.56
Procedural success (%) 100 100 1.0 100 100 1.00
Stenting of IRA (%) 100 100 1.0 100 100 1.00
Multiple stenting (%) 30 32 0.96 40 44 0.65
Abciximab use (%) 92 94 0.70 100 89 0.18
Total length of stenting (mm) 24 ± 11 21 ± 11 0.28 25 ± 9 25 ± 9 0.88
TIMI flow grade 3 after PCI (%) 100 100 1.0 100 100 1.0
Symptom onset to balloon time (min) 243 ± 187 238 ± 222 0.92 234 ± 142 256 ± 178 0.77
Procedural time (min) 32 ± 20 31 ± 16 0.75 33 ± 16 35 ± 17 0.73
TnI peak (ng/ml) 211 [97–413] 322 [167–418] 0.10 83[30–228] 99 [42–224] 0.61
CK-MB (IU/liter) 302 [165–437] 194 [209–485] 0.52 128 [43–265] 142 [87–307] 0.42
Pro-BNP Peak (pg/mL) 2,094 [1,671–5,887] 3,314 [2,002–4,846] 0.41 4,195[1,405–6,743] 4,983[3,470–10,880] 0.39
Aspirin (%) 98 94 0.94 100 100 1.00
Thienopyridine (%) 100 100 1.00 100 100 1.00
Statin (%) 100 100 1.00 100 100 1.00
Beta adrenergic blocker (%) 85 86 0.85 93 89 0.65
ACE inhibitor/ARB (%) 79 73 0.65 87 94 0.87
Continuous data are presented as mean ± SD or as median [interquartile range] when appropriate
ACE denotes angiotensin-converting enzyme, ARB angiotensin II receptor blocker, IRA infarct-related artery, LAD left anterior descending
artery, LVEF left ventricular ejection fraction, LVEDVi left ventricular end-diastolic volume index, LVESVi left ventricular end-systolic volume
index, PCI primary percutaneous coronary intervention, TIMI thrombolysis in myocardial infarction, TnI troponin I, CK-MB creatine kinase-MB,
BNP brain natriuretic peptide, R STe sum of ST-elevation
Page 4 of 9 Basic Res Cardiol (2014) 109:412
123
patients (86 %) with baseline TIMI flow grade B1 (54 % in
the doxycycline group and 46 % in the control group,
respectively), and 31 patients (94 %) with baseline TIMI
flow grade 2–3 (48 % in the doxycycline group and 52 % in
the control group) had 6-month echocardiographic examin-
ations suitable for the ventricular volume analysis (follow-up
rate 93 %).
Echocardiographic findings
The LVEDVi decreased from baseline to 6 months in the
patients with baseline TIMI flow grade 2–3 [-3 mL/m2
(IQR: -12 to 4 mL/m2)], while increased in those with
baseline TIMI flow grade B1 [6 mL/m2 (IQR: -2 to
14 mL/m2)], (p = 0.001) (Table 3). However, while
LVEDVi decrease from baseline to 6 months in the group
with TIMI flow grade 2–3 was similar regardless of drug
therapy, in the group with baseline TIMI flow grade B1,
the increase in LVEDVi was very low and significantly
lower in the doxycycline group as compared to the control
group [3 mL/m2 (IQR: -3 to 8 mL/m2) vs. 10 mL/m2
(IQR: 1–27 mL/m2), p = 0.006] (Fig. 1).
The LVESVi from baseline to 6 months decreased sig-
nificantly more in the group with baseline TIMI flow grade
2–3 than in the group with baseline TIMI flow grade B1
[-9 mL/m2 (IQR: -13 to -1 mL/m2) and -0.5 mL/m2
(IQR: -7 to 8 mL/m2), respectively, p = 0.001] (Table 3).
Particularly, in the group with baseline TIMI flow grade
2–3 LVESVi was reduced at 6 months regardless of drug
therapy, while in the group with baseline TIMI flow grade
B1 it had an opposite trend: it was reduced in the doxy-
cycline group, while it increased in the control group
[-3 mL/m2 (IQR: -10 to 3 mL/m2) vs. 4 (IQR: -2 to
14 mL/m2), p = 0.002] (Fig. 1).
The increase of LVEF was significantly greater in the
patients with baseline TIMI flow grade 2–3 compared to the
patients with baseline TIMI flow grade B1 (15 ± 11 vs.
8 ± 10 %, p = 0.003) (Table 3) and, among patients with
baseline TIMI flow grade B1, in the doxycycline group
respect to the control group (11 ± 11 and 4 ± 9 %,
respectively, p = 0.01) (Fig. 1).
Angiographic findings
A post-PCI TIMI flow grade 3 was achieved in all patients. The
6-month angiographic follow-up rate was 85 %. The IRA
patency was observed in all patients with TIMI flow grade 2–3
and in all but one in those with TIMI flow grade B1; there was
no difference in binary restenosis [50 % rate according to
Fig. 1 Echocardiographic changes from baseline to 6 months in the
group of patients with baseline TIMI flow grade B1 according to the
study therapy. The box comprises the interquartile range. The line in
the box is the median. The whiskers extend downwards to the lowest
value in the distribution and upwards to the largest value
Table 3 Six-month echocardiographic analysis according to the
baseline TIMI flow
Group 1
(TIMI flow B1)
Group 2
(TIMI flow 2–3)
p
Echocardiographic
analysis
n = 66 n = 31
D LVEDVi (mL/m2) 6 [-2 to 14] -3 [-12 to 4] 0.001
D LVESVi (mL/m2) -0.5 [-7 to 8] -9 [-13 to -1] 0.001
D LVEF (%) 8 ± 10 15 ± 11 0.003
Continuous data are presented as mean ± SD or as median [inter-
quartile range] when appropriate
DLVEDVi change of left ventricular end-diastolic volume index,
DLVESVi change of left ventricular end-systolic volume index,
DLVEF change of left ventricular ejection fraction
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study therapy in both groups: 17 vs. 18 % (p = 1.0) in the
group with TIMI flow grade B1, and 33 vs. 22 % (p = 0.69) in
the group with TIMI flow grade 2–3, respectively.
Contribution of doxycycline in LV remodeling
in patients with baseline TIMI flow B1
In Table 4A, the regression model is shown. The results of
step 1 indicate that the variance accounted for R2 with the
first seven independent variables (age, diabetes, hyperten-
sion, R ST-segment elevation pre-PCI and post-PCI, tro-
ponin I peak and pro-BNP peak), equaled to 0.39 which
was significantly different from zero (F change = 4.25,
p = 0.001). The step 2 (ACE inhibitors/ARBs, and beta
adrenergic blockers) did not significantly improved the
model (p = 0.48). By introducing the doxycycline in step
3, the change in variance (DR2) was equal to 0.06, which
was statistically significant (F change = 4.71, p = 0.03).
The results are similar when we used CK-MB peak as a
measure of the infarct size (Table 4B).
Discussion
This study shows that in patients with a first STEMI and
baseline occluded IRA, a timely short-term treatment
with doxycycline significantly reduces 6-month LV
remodeling.
Our data showed that persistence of residual blood flow
in the IRA is associated with a lower risk area, as indirectly
evaluated by pre-PCI R ST-segment elevation. This finding
is in agreement with what has been reported by Clements
et al. [1] and Ndrepepa et al. [3] by means of refined
imaging techniques. Earlier IRA blood-flow restoration,
whether spontaneously or pharmacologically induced, may
explain differences in the initial area of myocardium at
risk.
In agreement with previous studies [1, 3, 4] and with the
latest results obtained by De Luca et al. [2] on a large series
of over 790 patients treated by primary PCI, we also
observed that pre-procedural TIMI flow grade significantly
affected enzymatic final infarct size, even when an optimal
TIMI flow grade 3 post-PCI was obtained. This ominous
relationship between low baseline TIMI flow grade and
infarct size has been attributed to different factors resulting
from the longer time of ischemia [8], as well as micro-
embolization [7], blood clots and platelet plugs in the
microcirculation [9], and a greater myocardial reperfusion
injury [10]. Thus, it is not surprising that, in our study, the
patients with a baseline TIMI flow grade B1 showed a
more severe ventricular remodeling than patients with a
baseline TIMI flow grade 2–3.
The best characterized non-antimicrobial property of the
doxycycline is its ability to inhibit members of the MMP
family of endopeptidases [12], many of which are largely
up-regulated in the setting of animal [19–21] and human
[22, 23] hearts after MI. Previous studies have also shown
that doxycycline has some ability to inhibit reactive oxygen
species (ROS) [24]. Although we cannot exclude the pos-
sibility that doxycycline may have other protective effects
because of its reported pleiotropic actions including inhi-
bition of proinflammatory cytokines and ROS, it is plau-
sible that, to the plasma concentration achievable with the
dose of doxycycline used in our study [13], MMP inhibi-
tion, as opposed to ROS scavenging, may be the main
mechanism of its protective action [25]. Results of pre-
clinical studies show that the use of doxycycline in the first
7 days post-MI may exert a cardioprotective effect reduc-
ing LV remodeling [14, 15] and infarct size [26–28].
Recently, the TIPTOP trial confirmed the benefit of
Table 4 A and B Hierarchical multiple regression analysis of LVEDVi
change from baseline to 6 months in the patients with baseline TIMI
flow grade B1 correcting first for age, diabetes, hypertension, R STe pre-
PCI and post-PCI, Troponin I peak (A) or CK-MB peak (B), pro- BNP
peak, before entering ACE inhibitor/ARB and beta adrenergic blocker at
step 2, and then doxycycline at step 3
LVEDVi change from baseline to 6 months in the patients with baseline TIMI flow grade B1
Step Variables R R2 R2 change F change p
A
1 Age, diabetes, hypertension, R STe pre-PCI and post-PCI, troponin I peak, pro-BNP peak 0.62 0.39 0.39 4.25 0.001
2 ACE inhibitor/ARB, beta adrenergic blocker 0.64 0.41 0.02 0.75 0.48
3 Doxycycline 0.68 0.47 0.06 4.71 0.03
B
1 Age, diabetes, hypertension, R STe pre-PCI and post-PCI, CK-MB peak, pro-BNP peak 0.61 0.37 0.37 3.91 0.002
2 ACE inhibitor/ARB, beta adrenergic blocker 0.62 0.39 0.02 0.79 0.46
3 Doxycycline 0.68 0.46 0.07 5.56 0.02
R STe sum of ST-elevation, PCI primary percutaneous coronary intervention, BNP brain natriuretic peptide, ACE denotes angiotensin-converting
enzyme, ARB angiotensin II receptor blocker, CK-MB creatine kinase-MB
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doxycycline for the first time in the clinical setting of acute
STEMI [11]. In this post hoc analysis of the TIPTOP trial,
doxycycline was effective in reducing LV remodeling in
patients with acute STEMI and pre-PCI IRA TIMI flow
grade B1. Speculatively our results further support the idea
that doxycycline can exert some cardioprotective effects in
this clinical setting. Further future experimental and clini-
cal studies will answer the question whether doxycycline
has any effect on ROS generation or only acts downstream
of these blocking MMP proteolytic activity [29].
To examine the unique contribution of doxycycline in
the explanation of LV remodeling among patients with
TIMI flow grade B1, a hierarchical multiple regression
analysis was performed. The anti-remodeling effect of
doxycycline was independent from both the infarct size (as
measured by troponin I peak or CK-MB peak) and LV wall
stress (as indirectly expressed by pro-BNP peak), which are
the two most important drivers of the post-infarct remod-
eling process [30], and from advanced age that may criti-
cally contribute to remodeling process [31]. Moreover,
doxycycline appears to have more impact on LV remodel-
ing than the cornerstone of post-MI anti-remodeling therapy
probably because the unquestionable favorable clinical
effect of the latter drugs in patients with acute MI depends
on mechanisms other than inhibiting the LV dilation [32],
especially in the successfully reperfused patients [33].
Noteworthy, the anti-remodeling effect of doxycycline
occurs in patients with a baseline TIMI flow grade B1 but not
in those with a baseline TIMI flow grade 2–3. Likewise, in
the METOCARD-CNIC (effect of early metoprolol on
infarct size in ST-segment elevation myocardial infarction
patients undergoing primary PCI) trial [34] the infarct size in
the subgroup of patients with pre-PCI TIMI flow grade B1
was reduced by metoprolol to a larger extent than in the entire
study population. In other words, in the low-risk patients
with acute STEMI, such as those with a baseline TIMI flow
grade [1, the powerful salvaging capacity of primary PCI
with routine use of modern antithrombotic drugs over-
whelms the benefits of additional pharmacological cardio-
protective strategies, which could otherwise show benefit in
patients known to be at higher risk, such as those with TIMI
flow grade B1. The same finding has been demonstrated with
remote ischemic conditioning [35, 36], supporting that in
high risk patients the highest benefit beyond opening of the
IRA is achieved by additional intervention, that may be
pharmacological or mechanical [37–40].
Finally, pro-BNP level was higher in patients with
TIMI flow grade 2–3 on admission. This difference is non-
significant. However, it could be explained by a higher
prevalence of diabetes [2] in baseline open artery patients,
and diabetes per se is a strong factor for increased plasma
pro-BNP level after myocardial infarction [41]. However,
at the multivariable analysis the anti-remodeling effect of
doxycycline is found to be independent also from pro-
BNP level.
The present analysis is subjected to some limitations.
First, this is a post hoc analysis of a small trial and the
results can be considered only hypothesis generating.
Second, without an assessment of infarct size by perfusion
imaging at baseline, a selection bias favoring doxycycline
therapy arm cannot be excluded. However, the indirect
measures of the area at risk, myocardial reperfusion
effectiveness, and enzymatic infarct size did not differ
between groups. Third, the patients were treated with
standard-of-care therapy for STEMI, accordingly to the
current ESC guidelines, with the exception of the miner-
alocorticoid antagonists which were used in one-fourth of
the patients with the indication to this specific treatment;
this was in part due to the temporal trend of study enroll-
ment that started in early 2007, almost 2 years before the
implementation of the use of MRA in the ESC guidelines
for STEMI patient [42]. It is, therefore, possible that the
magnitude of the benefit we have observed with doxycy-
cline might be reduced by treating with a MRA all the
patients with this indication. Fourth, 7 survived patients
(6.3 %) were lost to 6-month echocardiographic follow-up.
There were no significant differences between participants
who were lost to follow-up and all those who were inclu-
ded in the present study in terms of baseline characteristics.
Therefore, the potential bias regarding the participants lost
to follow-up may be negligible.
In conclusion, timely administration of doxycycline in
the STEMI patients at higher risk, as those with a baseline
occluded IRA, is associated with a significant reduction in
LV remodeling as compared to control.
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